Hepatitis B virus (HBV) reactivation in carriers undergoing immunosuppressive therapy is well documented
However, the efficacy of antiviral prophylaxis in these patients is unclear.
In this study, doctors from Turkey and the United States assessed lamivudine prophylaxis in HBV carriers with hemato/oncological malignancies, who received chemotherapy.
The team evaluated 18 HBV carriers with malignancy.
Of these, 8 patients were enrolled for prophylactic lamivudine therapy. The remaining 10 controls did not receive prophylactic therapy.
The team began lamivudine treatment on the same day as the patient received chemotherapy. Lamivudine was maintained for a year after chemotherapy was discontinued.
The team did not find any HBV-related mortality in either group.
|50% of the control group experienced HBV reactivation.|
|Journal of Viral Hepatitis|
They identified no evidence of HBV reactivation in the lamivudine group. However, 50% of the control group experienced a reactivation of HBV infection.
The reactivation occurred during chemotherapy in 4 patients.
No lamivudine-related major adverse effects were observed.
Dr Idilman's team concluded, "Prophylactic lamivudine treatment in HBV carriers with hemato/oncological malignancy receiving chemotherapy prevents chemotherapy-induced HBV reactivation".